BUSINESSQUARTZ
Unilever is exploring a bid for supplements maker Thorne in a potential $4 billion deal
Unilever is considering a bid for Thorne, a supplements maker, in a potential $4 billion deal. L Catterton, a private equity firm backed by LVMH, acquired Thorne for $680 million in 2023 and is now seeking a valuation of up to $4 billion.
Related Signal
Adjacent reporting
- Aquarian Seeks More Backers for $4.1 Billion Brighthouse Deal
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
- CVC, GTCR Weigh Take-Private of Medical Equipment Provider Teleflex
- Centerbridge in talks to buy stake in $3bn real estate firm
- STAT+: Roche to buy PathAI for $750 million
- Italy’s Angelini Said to Explore Catalyst Pharma Acquisition